"Tokyo 172" BCG vaccine designed for percutaneous inoculation is widely used in Japan. This vaccine is a much higher concentration of M. bovis BCG than that of the BCG vaccine designed for intradermal inoculation widely used in other countries. A patient who suffered from an ulcerous skin lesion as a result of the intradermal injection of "Tokyo 172" BCG vaccine accidentally was referred to our hospital. Systemic corticosteroid was administered with anti-tuberculous drugs, achieving a complete improvement of the skin lesion.